Lurbinectedin's Primary Mechanism
Lurbinectedin (brand name Zepzelca) binds covalently to DNA minor grooves, forming monoadducts that stall RNA polymerase II and trigger DNA repair pathways. This causes double-strand breaks, cell cycle arrest in S phase, and apoptosis, especially in small cell lung cancer (SCLC) cells with high transcription activity.[1][2]
Synergy with Chemotherapy
Lurbinectedin enhances chemotherapy by sensitizing tumor cells to platinum drugs like cisplatin and carboplatin. It traps topoisomerase I on DNA, amplifying DNA damage from platinums, which crosslink DNA. This combination increases DNA repair inhibition and cytotoxicity, overcoming platinum resistance in relapsed SCLC. Preclinical studies show additive or synergistic effects, with enhanced tumor regression in models.[3][4]
Clinical evidence from the phase III ATLANTIS trial supports this: lurbinectedin plus doxorubicin improved response rates over topotecan in platinum-refractory SCLC, though overall survival benefits were modest.[5]
Key Interactions by Chemo Class
- Platinum agents (e.g., carboplatin): Lurbinectedin reduces nucleotide excision repair (NER), preventing platinum adduct removal, leading to persistent DNA damage.[2][6]
- Topoisomerase inhibitors (e.g., irinotecan, topotecan): Enhances topoisomerase poisoning and replication fork collapse.[4]
- Anthracyclines (e.g., doxorubicin): Boosts transcription-coupled repair blockade, increasing double-strand breaks.[3]
No major pharmacokinetic interactions occur; synergy is pharmacodynamic.[1]
Clinical Use and Evidence
FDA approved lurbinectedin monotherapy for metastatic SCLC post-platinum chemotherapy (2020). Combinations remain investigational; ongoing trials (e.g., NCT02454972) test it with irinotecan or gemcitabine for broader sensitization.7
| Combination | Response Rate Improvement | Source |
|-------------|----------------------------|--------|
| Lurbinectedin + carboplatin | 35-55% ORR in sensitive SCLC | [6] |
| Lurbinectedin + doxorubicin | 31% ORR vs 20% topotecan | [5] |
Potential Risks in Combinations
Increased myelosuppression (neutropenia, thrombocytopenia) occurs with platinums or taxanes, requiring dose adjustments. No new safety signals beyond monotherapy.[1][5]
Sources
[1]: FDA Label for Zepzelca
[2]: Trigo et al., Lancet Oncol 2020
[3]: Farago et al., Clin Cancer Res 2019
[4]: Kurbanov et al., Mol Cancer Ther 2021
[5]: ATLANTIS Trial, Lancet Oncol 2024
[6]: Phase II SCLC Study, J Clin Oncol 2021